Dedicated to discovering, developing, and commercializing novel therapeutics to transform the treatment of patients with grievous blood-based disorders


GBT (NASDAQ: GBT) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT’s lead product candidate is voxelotor (formerly known as GBT440), an oral, once-daily therapy that modulates hemoglobin’s affinity for oxygen, which the company believes inhibits hemoglobin polymerization in sickle cell disease.


Year Invested: 2012
Location: South San Francisco, Calif.
Visit: www.gbt.com/

Recent News

April 3, 2018
GBT Announces Participation at the H.C. Wainwright Global Life Sciences Conference

April 3, 2018
GBT Announces New Employment Inducement Grants

March 15, 2018
GBT Announces New Employment Inducement Grants

Read More News

Associated Team Members

Kevin Starr
Partner

Craig Muir
Partner/Chief Technology Officer

Charles Homcy, M.D.
Partner

Glenn Pierce, M.D., Ph.D.
Entrepreneur-in-Residence